Children exposed to valproate in utero had a 48% increased risk of developing attention-deficit/hyperactivity disorder (ADHD), compared with children with no exposure to the drug, according to a new study.


According to Teva Pharmaceutical Industries, Ltd., the FDA has announced approval of the generic version of Adderall XR®, a popular drug for the treatment of attention-deficit/hyperactivity disorder (ADHD).

ADHD Emergency Department

The overall number of emergency department (ED) visits involving attention deficit/hyperactivity disorder (ADHD) medications more than doubled between 2005 and 2010, going from 13,379 visits to 31,244 visits, according to a report by the Substance Abuse Mental Health Services Administration (SAMHSA).